

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

INSIDE INFORMATION

POTENTIAL DISPOSAL OF EQUITY INTEREST IN BNIBT THROUGH PUBLIC TENDER

This announcement is made by China Isotope & Radiation Corporation (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of the Hong Kong).

POTENTIAL DISPOSAL THROUGH PUBLIC TENDER

The board of directors (the “**Board**”) of the Company announces that the Company intends to dispose of 100% equity interest held by the Company in Beijing North Institute of Biotechnology Co., Ltd (北京北方生物技術研究所有限公司) (“**BNIBT**”) by way of transfer through a public tender process on the China Beijing Equity Exchange (北京產權交易所) (“**CBEX**”) (the “**Potential Disposal**”). In compliance with the relevant regulatory requirements of the PRC, a preliminary disclosure of information in relation to the Potential Disposal (the “**Preliminary Disclosure**”) has also been made to the public on the website of CBEX on the date of this announcement.

The base price of the Potential Disposal is determined based on the appraisal value of BNIBT as conducted by a reputable valuer.

REASONS FOR AND BENEFITS OF THE POTENTIAL DISPOSAL

BNIBT, a wholly-owned subsidiary of the Company in the in vitro diagnosis business segment, has nearly 40 years of rich experience in the field of radio-immunity. Affected by the internal and external environments, BNIBT is faced with huge development opportunities and challenges, and requires new development vitality in the form of capital. The Company intends to introduce strategic investors for BNIBT to optimize its shareholding and governance structure, revitalize its existing assets, create industry synergy and empowerment, and make full use of the capital market to promote the operation and development of BNIBT and enhance its corporate image. The Board is of the view that the Potential Disposal, if materialised, is beneficial to the Group and will not have any adverse impact on the business and financial performance of the Group.

INFORMATION ON BNIBT

BNIBT, a wholly-owned subsidiary of the Company, is principally engaged in the research, development, manufacturing and sale of in vitro diagnostic reagents, and its business covers the manufacturing of raw materials in the upstream business and products, scientific research service and other industrial chain businesses in the in vitro diagnosis segment. As at the date of this announcement, the Company holds 100% equity interest in BNIBT.

GENERAL

The Preliminary Disclosure is only for information disclosure in advance, and does not constitute a transaction under Chapter 14 of the Listing Rules. The Potential Disposal, if materialised, may constitute a discloseable transaction of the Company. The Company will make further announcement with respect to any major update and progress of the Potential Disposal as and when appropriate in compliance with applicable legal and regulatory requirements.

Shareholders and potential investors of the Company should note that as the Potential Disposal is only at the Preliminary Disclosure stage, the Potential Disposal may or may not materialise. Shareholders and potential investors of the Company should be aware that there is no assurance that the Potential Disposal will materialise or as to when it may materialise. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the share(s) of the Company.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms and expressions have the meanings set forth below:

“Director(s)”	director(s) of the Company
“Group”	the Company and its subsidiaries
“PRC” or “China”	the People’s Republic of China, excluding, for the purpose of this announcement only, Hong Kong, Macau Special Administrative Region and Taiwan
“%”	per cent.

By order of the Board
China Isotope & Radiation Corporation
Wang Suohui
Chairman

Beijing, the PRC, 8 September 2023

As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.